Filgrastim Recruiting Phase 2 Trials for Malignant Lymphomas Treatment

IndicationsStatusPurposePhase
RecruitingTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT02436707Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma